Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Thomas R. Slaney"'
Autor:
Rosendo C. Villafuerte-Vega, Henry W. Li, Thomas R. Slaney, Naresh Chennamsetty, Guodong Chen, Li Tao, Brandon T. Ruotolo
Publikováno v:
Analytical Chemistry. 95:6962-6970
Autor:
Cara I. D’Amico, Gillian Robbins, Iris Po, Zhichao Fang, Thomas R. Slaney, Gabi Tremml, Li Tao, Brandon T. Ruotolo, Robert T. Kennedy
Publikováno v:
Journal of the American Society for Mass Spectrometry.
Autor:
Björn‐Hendrik Peters, James Bautista, Thomas R. Slaney, Hongyue Guo, Richard Y.‐C. Huang, Mary E. Krause, Ming Zeng, Julie Cheng, Zhi Chen
Publikováno v:
Electrophoresis6 References. 43(9-10)
Antibody-based therapeutic proteins have highly complex molecular structures. The final therapeutic protein product may contain a wide range of charge variants. Accurate analysis of this charge variant composition is critical to determine manufacturi
Autor:
Magfur E. Alam, Thomas R. Slaney, Peter M. Tessier, Sambit R. Kar, Tapan K. Das, Anthony Leone, Lina Wu, Gregory V. Barnett
Publikováno v:
Journal of Pharmaceutical Sciences. 109:656-669
Monoclonal antibodies are attractive therapeutic agents because of their impressive biological activities and favorable biophysical properties. Nevertheless, antibodies are susceptible to various types of chemical modifications, and the impact of suc
Publikováno v:
Analytical chemistry. 92(15)
Liquid chromatography-mass spectrometry (LC-MS)-based proteomics approaches have been widely used to identify residual host-cell proteins (HCPs) in support of process and product characterization for protein therapeutics. Particularly, these methods
Autor:
Gargi Gupta, Tapan K. Das, Wei Wu, Li Tao, Erik Langsdorf, Richard Ludwig, Thomas R. Slaney, Hangtian Song, Tao Jiang, Duncan McVey
Publikováno v:
Analytical Chemistry. 89:12749-12755
Recombinant monoclonal antibodies (mAbs) manufactured from immortalized mammalian cell lines are becoming increasingly important as therapies. Ensuring the quality of expressed proteins is critical when developing manufacturing processes. Protein seq
Autor:
Girija Krishnamurthy, Sheetal Mehta, Lei Zhang, Harbhajan Dhillon, Hangtian Song, Heather Boux, Deepti Ahluwalia, Anulfo Valdez, Thomas R. Slaney
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 141:32-38
Residual host cell proteins (HCPs) are process-related impurities present in biotherapeutics that can pose safety health risks to patients. An adequate control of HCP levels in the final product, and demonstration of HCP clearance throughout a produc
Autor:
Tapan K. Das, Gregory V. Barnett, Charles G. Starr, Thomas R. Slaney, Peter M. Tessier, Magfur E. Alam
Publikováno v:
Molecular pharmaceutics. 16(5)
Monoclonal antibodies must be both chemically and physically stable to be developed into safe and effective drugs. Although there has been considerable progress in separately understanding the molecular determinants of antibody chemical and physical
Autor:
Tapan K. Das, Thomas R. Slaney, Yunping Huang, Sambit R. Kar, Anthony Leone, Gurusamy Balakrishnan, Li Tao, Gregory V. Barnett, Laurel Hoffman, Jacob Bongers, Naresh Chennamsetty
Publikováno v:
Journal of pharmaceutical sciences. 108(6)
Tryptophan (Trp) oxidation in proteins leads to a number of events, including changes in color, higher order structure (HOS), and biological activity. We describe here a number of new findings through a comprehensive characterization of 6 monoclonal
Publikováno v:
Protein Analysis using Mass Spectrometry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10d2709b335d80fcae993e44785644b1
https://doi.org/10.1002/9781119371779.ch16
https://doi.org/10.1002/9781119371779.ch16